Current Liabilities
Gilead Sciences·Balance Sheet Statement·7 metrics
Breakdown
| Metric | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Total current liabilities | $10.8B | $11.7B | $12B | $12.3B | $11.2B | $12.3B | $11.8B | $9.5B |
| Accrued rebates | $3.9B | $4.1B | $3.9B | $4.2B | $4.2B | $4.9B | $4.3B | $4.1B |
| Other accrued liabilities | $4.5B | $4.9B | $5.5B | $4.6B | $3.6B | $3.8B | $4B | $3.4B |
| Current portion of long-term debt | $1.8B | $1.8B | $1.8B | $2.8B | $2.8B | $2.8B | $2.8B | $1.3B |
| Accounts payable | $537M | $903M | $833M | $737M | $582M | $808M | $715M | $645M |
| Sales Discounts and Allowances | $92M | $89M | $89M | $90M | $95M | $97M | $97M | $98M |
| Derivative Liabilities - Fair Value | $2M | $7M | $3M | $25M | $7M | $29M | $40M | $24M |